GLP1-S

Description

Semaglutide is a modified synthetic analogue of human Glucagon-Like Peptide-1 (GLP-1). It shares 94% structural homology with native human GLP-1 but has been chemically engineered for significantly increased albumin binding.

This structural modification protects the peptide from enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), extending its half-life in research subjects from minutes (native GLP-1) to approximately one week. As a selective GLP-1 receptor agonist, Semaglutide is the “gold standard” substrate for researching incretin pathways. It functions by mimicking the body’s natural physiological response to nutrient intake: stimulating glucose-dependent insulin secretion, suppressing inappropriate glucagon release, and slowing gastric motility.

Key Research Applications

• Metabolic Regulation & Satiety: Semaglutide is the most extensively studied peptide for investigating energy homeostasis. Research demonstrates its ability to act on the hypothalamus to decrease appetite and food cravings, while simultaneously delaying gastric emptying to prolong satiety signals.

• Cardiovascular & Endothelial Health: Beyond weight, Semaglutide is investigated for its anti-inflammatory effects on the cardiovascular system. Studies (such as the SELECT trial data) suggest it may reduce major adverse cardiovascular events (MACE) in test subjects independent of weight reduction, highlighting a direct protective mechanism on arterial walls.

• Neuroprotection (Alzheimer’s/Parkinson’s): A rapidly growing field of study involves GLP-1 receptors in the brain. Semaglutide is currently being investigated in neurodegenerative models for its potential to reduce neuroinflammation, improve glucose transport across the blood-brain barrier, and protect dopaminergic neurons.

⚠️ FOR RESEARCH PURPOSES ONLY This product is intended for laboratory research and development use only. It is not intended for human consumption, diagnostic, or therapeutic use. Handle with care and adhere to all laboratory safety protocols.